Gland Pharma Limited, a generic injectablefocused pharmaceutical company, announced its financial results for the second quarter ended September 30, 2025.

Gland Pharma reported a 12 per cent year-on-year increase in net profit to Rs. 184 crore in Q2 FY26 as compared to Rs. 163 crore in Q2 FY25 , driven by growth in the US and European markets.

Revenue for the quarter rose 5.8 per cent to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal.  EBITDA margin remained stable at 21.1 per cent. The company also highlighted strong growth in its half-year performance, with a 7 per cent revenue increase and a 21 per cent rise in EBITDA.

Commenting on the results, Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders.”

Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during the Q2 FY26 with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi. With the current momentum, we anticipate a robust growth in the upcoming quarters.”